Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lantern Pharma ( (LTRN) ) just unveiled an update.
On July 3, 2025, Lantern Pharma Inc. entered into an ATM Sales Agreement with ThinkEquity LLC to offer and sell up to $15,530,000 of common stock. This agreement allows the company to strategically raise capital through at-the-market offerings, potentially enhancing its financial flexibility and market positioning.
The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.
Spark’s Take on LTRN Stock
According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.
Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.
To see Spark’s full report on LTRN stock, click here.
More about Lantern Pharma
Lantern Pharma Inc. operates within the biotechnology industry, focusing on developing precision oncology therapies. The company leverages advanced genomics and machine learning to identify and develop targeted cancer treatments.
Average Trading Volume: 54,108
Technical Sentiment Signal: Strong Sell
Current Market Cap: $33.97M
See more data about LTRN stock on TipRanks’ Stock Analysis page.